National Association of Testing Authorities, Australia
Scope of Accreditation
Northern Sydney Local Health District - Kolling Institute
Site
Cancer Genetics Diagnostic Laboratory – Kolling Institute
Accreditation No.
19626
Site No.
22731
Date of Accreditation
09 Dec 2014
Address
Level 9, Kolling Institute, Royal North Shore Hospital
St Leonards, NSW 2065
Australia
Contact
Availability
Services available to external clients
Supervision
S (Specialised)
Scope of Accreditation
ISO 15189 (2022)
- This facility complies with the relevant National Pathology Accreditation Advisory Council (NPAAC) requirements.
Human Pathology
Medicare expiry date
28 Feb 2027
Last Activity Date
09 Aug 2022
Service | Product | Determinant |
---|---|---|
Molecular genetics - Assay for defined mutation or polymorphism (including pharmacogenetic testing) - Targeted genes | Blood; Extracted DNA | Calcium sensing receptor (CaSR gene mutation); Hyperparathyroidism - Jaw tumour syndrome; Medullary thyroid cancer (RET gene mutation); Multiple endocrine neoplasia type 2 (MEN2); Nucleic acid analysis for specific variants; Parathyroid hormone (PTH); Sporadic and inherited neuroendocrine syndromes - Phaeochromocytomas and paragangliomas - SDHD,B,C,A TMEM127, fumarate hydratase, MAX gene mutations; Thyroid hormone receptor (THRB gene mutation); Thyroid stimulating hormone receptor (TSHR); Vitamin D 24-hydroxylase; Von Hippel Lindau disease |
Hyperparathyroidism - Jaw tumour syndrome; Paragangliomas; Von Hippel Lindau disease | ||
Blood; Formalin-fixed paraffin-embedded (FFPE) tissues | Somatic RET for medullary thyroid carcinoma (variant and loss of heterozygocity) | |
Molecular genetics - Assay for defined mutation or polymorphism (including pharmacogenetic testing) - Targeted panels for inherited (germline) DNA/RNA changes | Blood; Extracted DNA | Hyperparathyroidism - Jaw tumour syndrome; Parathyroid hormone (PTH); Thyroid stimulating hormone receptor (TSHR); Vitamin D 24-hydroxylase |
Hyperparathyroidism - Jaw tumour syndrome; Paragangliomas; Von Hippel Lindau disease | ||
Molecular genetics - Heterozygous loci determinations | Blood; Extracted DNA | Hyperparathyroidism - Jaw tumour syndrome; Paragangliomas; Von Hippel Lindau disease |
Molecular genetics - Investigation of constitutional genetic variants - Carrier testing - Targeted genes | Blood; Extracted DNA | Hyperparathyroidism - Jaw tumour syndrome; Parathyroid hormone (PTH); Thyroid stimulating hormone receptor (TSHR); Vitamin D 24-hydroxylase |
Hyperparathyroidism - Jaw tumour syndrome; Paragangliomas; Von Hippel Lindau disease | ||
Calcium sensing receptor (CaSR gene mutation); Medullary thyroid cancer (RET gene mutation); Multiple endocrine neoplasia type 2 (MEN2); Nucleic acid analysis for specific variants; Sporadic and inherited neuroendocrine syndromes - Phaeochromocytomas and paragangliomas - SDHD,B,C,A TMEM127, fumarate hydratase, MAX gene mutations; Von Hippel Lindau disease | ||
Molecular genetics - Investigation of constitutional genetic variants - Carrier testing - Targeted panels for inherited (germline) DNA/RNA changes | Blood; Extracted DNA | Hyperparathyroidism - Jaw tumour syndrome; Paragangliomas; Von Hippel Lindau disease |
Molecular genetics - Investigation of constitutional genetic variants - Diagnostic testing - Targeted genes | Blood; Extracted DNA | Calcium sensing receptor (CaSR gene mutation); Hyperparathyroidism - Jaw tumour syndrome; Medullary thyroid cancer (RET gene mutation); Multiple endocrine neoplasia type 2 (MEN2); Nucleic acid analysis for specific variants; Parathyroid hormone (PTH); Sporadic and inherited neuroendocrine syndromes - Phaeochromocytomas and paragangliomas - SDHD,B,C,A TMEM127, fumarate hydratase, MAX gene mutations; Thyroid hormone receptor (THRB gene mutation); Thyroid stimulating hormone receptor (TSHR); Von Hippel Lindau disease |
Molecular genetics - Investigation of constitutional genetic variants - Diagnostic testing - Targeted panels for inherited (germline) DNA/RNA changes | Blood; Extracted DNA | Hyperparathyroidism - Jaw tumour syndrome; Parathyroid hormone (PTH); Thyroid stimulating hormone receptor (TSHR); Vitamin D 24-hydroxylase |
Calcium sensing receptor (CaSR gene mutation); Medullary thyroid cancer (RET gene mutation); Multiple endocrine neoplasia type 2 (MEN2); Nucleic acid analysis for unknown variants; Sporadic and inherited neuroendocrine syndromes - Phaeochromocytomas and paragangliomas - SDHD,B,C,A TMEM127, fumarate hydratase, MAX gene mutations; Thyroid hormone receptor (THRB gene mutation); Von Hippel Lindau disease | ||
Molecular genetics - Predictive genetic testing - Targeted genes | Blood; Extracted DNA | Calcium sensing receptor (CaSR gene mutation); Medullary thyroid cancer (RET gene mutation); Multiple endocrine neoplasia type 2 (MEN2); Nucleic acid analysis for specific variants; Sporadic and inherited neuroendocrine syndromes - Phaeochromocytomas and paragangliomas - SDHD,B,C,A TMEM127, fumarate hydratase, MAX gene mutations; Thyroid hormone receptor (THRB gene mutation); Von Hippel Lindau disease |
Hyperparathyroidism - Jaw tumour syndrome; Thyroid stimulating hormone receptor (TSHR); Vitamin D 24-hydroxylase | ||
Hyperparathyroidism - Jaw tumour syndrome; Paragangliomas; Von Hippel Lindau disease | ||
Molecular genetics - Predictive genetic testing - Targeted panels for inherited (germline) DNA/RNA changes | Blood; Extracted DNA | Hyperparathyroidism - Jaw tumour syndrome; Paragangliomas; Von Hippel Lindau disease |
Molecular genetics - Screening for an unknown mutation - Targeted genes | Blood; Extracted DNA | Hyperparathyroidism - Jaw tumour syndrome; Paragangliomas; Von Hippel Lindau disease |
Calcium sensing receptor (CaSR gene mutation); Medullary thyroid cancer (RET gene mutation); Multiple endocrine neoplasia type 2 (MEN2); Nucleic acid analysis for unknown variants; Sporadic and inherited neuroendocrine syndromes - Phaeochromocytomas and paragangliomas - SDHD,B,C,A TMEM127, fumarate hydratase, MAX gene mutations; Thyroid hormone receptor (THRB gene mutation); Von Hippel Lindau disease | ||
Hyperparathyroidism - Jaw tumour syndrome; Parathyroid hormone (PTH); Thyroid stimulating hormone receptor (TSHR); Vitamin D 24-hydroxylase | ||
Molecular genetics - Screening for an unknown mutation - Targeted panels for inherited (germline) DNA/RNA changes | Blood; Extracted DNA | Calcium sensing receptor (CaSR gene mutation); Medullary thyroid cancer (RET gene mutation); Multiple endocrine neoplasia type 2 (MEN2); Nucleic acid analysis for unknown variants; Sporadic and inherited neuroendocrine syndromes - Phaeochromocytomas and paragangliomas - SDHD,B,C,A TMEM127, fumarate hydratase, MAX gene mutations; Von Hippel Lindau disease |
Hyperparathyroidism - Jaw tumour syndrome; Paragangliomas; Von Hippel Lindau disease | ||
Hyperparathyroidism - Jaw tumour syndrome; Parathyroid hormone (PTH); Thyroid stimulating hormone receptor (TSHR); Vitamin D 24-hydroxylase |
The only data displayed is that deemed relevant and necessary for the clear description of the activities and services covered by the scope of accreditation.
Grey text appearing in a SoA is additional freetext providing further refinement or information on the data in the preceding line entry.
Accreditation No.
19626
Site No.
22731
Print date
27 Nov 2024